fda and glp-1 News Brief: Seeks Removal of Suicidal Behavior Warning for RA Medications FDA on GLP-1 compounders and

It cannot differentiate intramuscular triglycerides from contractile protein

If GLP-1 is detectable in synovial fluid, that supports the biological plausibility that GLP-1-based therapies could potentially act directly in the joint as well as systemically. Tue Wenzel Kragstrup, MD, PhD After comparing participants blood and joint fluid samples to those from healthy volunteers, researchers detected small amounts of the bodys natural GLP-1 hormone in joint fluid

Even when a peptide is legal to prescribe, most growth-hormone-releasing peptides are banned by the World Anti-Doping Agency, the NCAA, and the U.S

Results were presented at the 2024 European Renal Association Congress in Stockholm, Sweden, and published in The New England Journal of Medicine (1)

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial

In theory, they are complementary